BIOMNIS Report issue

For profit Phase 3
Founded: Lyon France (1897)
Status: Acquired by Eurofins (2015)

Organization Overview

First Clinical Trial
2010
NCT01120405
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOMNIS Central laboratory

Active Ingredients

Drugs in Phase 3 Trials (4)

leucovorin (1 trial)

levothyroxine (Synthroid) (1 trial)

sevoflurane (ultane) (1 trial)

xenon xe-133 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Down Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4